Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents

Psychopharmacology

Volumn 138, Issue 1, 1998, Pages 67-75

  Marona Lewicka, Danuta ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

5 HT releasers; Drug discrimination; Interoceptivtr cue; MMAI; Rats; SSRIs; Tricyclic antidepressants

Indexed keywords

1 (1,3 BENZODIOXOL 5 YL) N METHYL 2 BUTANAMINE; 5 METHOXY 6 METHYL 2 INDANAMINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); FLUOXETINE; INDANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0031850091     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050646     Document Type: Article

References (45)

1. Andrews JS, Stephens DN (1990) Drug discrimination models in anxiety and depression. Pharmacol Ther 47: 267-280
2. Artigas F (1993) 5-HT and antidepressunts: new views from microdialysis studies. Trends Pharmacol Sci 14: 262-264
3. 1A activity in the discriminative stimulus effects of imipramine. Pharmacol Biochem Behav 38: 407-410
4. Bell N, Artigas F (1992) Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 232: 101-103
5. Blister RD, Becker RE (1985) Characterization of the bupropion cue in the rat: lack of evidence for dopaminergic mechanism. Psychopharmacology 85: 173-177
6. Brodkin J, Malyala A, Nash JF (1993) Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 45: 647-653
7. Carboni E, Di Chiara G (1989) Serotonin release estimated by transcortical dialysis in freely moving rats. Neuroscience 32: 637-645
8. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115: 1064-1070
9. Goudie AJ, Leathley MJ (1993) Drug discrimination assays. In: Sahgal A (ed) Behavioural neuroscience: a practical approach (vol 2). Oxford University Press, New York, pp 145-168
10. Goudie AJ, Dubicki W, Leathley M (1988) Paroxetinc, a selective 5-hydroxytryptamine uptake inhibitor with antidepressant properties, lacks amphetamine-like stimulus properties in an operant drug discrimination bioassay in rodents. J Pharm Pharmacol 40: 192-196
11. Gu XF, Azmita EC (1993) Integrative transporter-mediated release from cyloplasmic and vesicular 5-hydroxytryplamine stores in cultured neurons. Eur J Pharmacol 235: 51-57
12. Huang X, Marona-Lewicka D, Nichols DE (1992) p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol 229: 31-35
13. Hutson PH, Curzon G (1989) Concurrent determination of the effects of p-chloroamphetamine on central extracellular 5-hydroxytryptamine concentration and behaviour. Br J Pharmacol 96: 801-806
14. Invernizzi R, Belli S, Samanin R (1992) Citalopram's ability to increase the extracellular concentrations of serolonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584: 322-324
15. Johnson AM (1991) The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Feighner JP, Boyer WF (eds) Selective serotonin re-uptake inhibitors. The clinical use of citalopram, fluoxetine and sertraline. Wiley, Chichester New York Brisbane, pp 37-70
16. 3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 200: 9-14
17. Johnson MP, Frescas SP, Oberlender R, Nichols DE (1991b) Synthesis and pharmacological examination of 1-(3-methoxy-4-methyl-phenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan. Similarities to 3,4-(methylenedioxy)-metham-phetamine (MDMA). J Med Chem 34: 1662-1668
18. Jones CN, Howard JL, McBennet ST (1980) Stimulus properties of antidepressants in the rat. Psychopharmacology 67: 111-118
19. Kreiss DS, Wieland S, Luck I (1993) The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release. Neuroscience 52: 295-301
20. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99-112
21. Malagie I, Trillat AC, Jacquot C, Gardier A (1996) Effects of acute fluoxetine on extracellular levels in the raphe: an in vivo microdialysis study. Eur J Pharmacol 286: 213-217
22. Marona-Lewicka D, Nichols DE (1994) Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol 258: 1-13
23. Nash JF, Nichols DE (1991) Microdialysis studies of 3,4-methyle-nedioxymeth amphetamine and structurally related analogues. Eur J Pharmacol 200: 53-58
24. Nichols DE, Oberlender R (1990) Structure-activity relationship of MDMA and related compounds: a new class of psychoactive drugs? Ann NY Acad Sci 600: 613-623
25. Nichols DE, Hoffman RA, Oberlender RA, Jakob III P, Shulgin AT (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine. Representative of a novel therapeutic class. J Med Chem 29: 2009-2016
26. Nichols DE, Marona-Lewicka D, Huang X, Johnson MP (1993) Novel serotonergic agents. Drug Design and Discovery 9: 299-312
27. Oberlender R, Nichols DE (1988) Drug discrimination studies with MDMA and amphetamine. Psychopharmacol 95:71-76
28. Oberlender R, Nichols DE (1990) (+)-N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy methamphetamine-like behavioral activity. J Pharmacol Exp Ther 255: 1098-1106
29. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803
30. Olivier B, Bosch L, van Hest A, van der Heyden J, Mos J, van der Poel G, Schipper J, Tulp M (1993) Preclinical evidence on the psychotropic profile of fluvoxamine. Pharmacopsychiatry 26 [Suppl]: 2-9
31. Overton DA, Batta SK (1977) Relationship between abuse liability of drugs and their degree of discriminability in the rat. In: Thomson T, Unna KR (eds) Predicting liability of stimulant and depressant drugs. University Park Press, Baltimore, pp 125-135
32. Preskorn SH (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32 [Suppl 1]: 1-21
33. Puzynski S (1986) Leki przeciwdepresyjne. In: Kostowski W, Puzynski S (eds) Psychofarmakologia doswiadczalna i kliniczna. Panstwowy Zaklad Wydawnictw Lekarskich, Warszawa. pp 282-346
34. 1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J Neurochem 68: 2593-2603
35. Rudnick G, Wall SC (1993) Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters. Mol Pharmacol 43: 271-280
36. Rutter JJ, Gundlah C, Auerbach SB (1995) Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse 20: 225-233
37. Sanders-Bush E, Martin LL (1982) Storage and release of serotonin. In: Osborne NN (ed) Biology of serotonergic transmission. Wiley, Chichester, pp 95-118
38. Schechter MD (1983) Discriminative stimulus control with imipramine: transfer to other antidepressants. Pharmacol Biochem Behav 19: 751: 754
39. Schechter MD, Signs SA, Boja JW (1989) Stability of the stimulus properties of drugs over time. Pharmacol Biochem Behav 32: 361-364
40. 125I]RTI-55. Synapse 16: 263-268
41. Series HG, Cowen PJ, Sharp T (1994) p-Chloroamphetamine (PCA), 3,4-methylenedioxymethamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology 116: 508-514
42. Sherman G, Miksic S, Lal H (1978) Discriminative stimulus properties of desipramine. Neuropharmacology 17: 1045-1048
43. Shulgin A, Shulgin A (1991) PIHKAL. Transform Press, Berkeley, Calif.
44. Stanford SC (1995) Prozac: panacea or puzzle? Trends Pharmacol Sci 17: 150-154
45. Zhang L, Barrett JE (1991) Imipramine as a discriminative stimulus. J Pharmacol Exp Ther 259: 1088-1093